With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management. Among incretin-based drugs, glucagon-like peptide1(GLP-1) receptoragonistsare a ...
AbstractDiabeticKidney Disease (DKD) is the leading cause of end stage renal disease (ESRD) worldwide. Glucagon-like peptide1receptoragonists(GLP-1RAs) are now widely used in the treatment of patients with type 2 diabetes (T2D).
Additionally,GLP-1reduces glucagon secretion by islet α cells, slows gastric emptying, and reduces appetite through effects on the hypothalamus.1GLP-1receptoragonists(GLP-1RAs) were therefore developed as drugs for the treatment of type 2 diabetes.
Summary Glucagon-like peptide-1 (GLP-1) receptoragonistsare incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.
Glucagon-like peptide-1 (GLP-1) receptoragonistsprovide renoprotective benefits in diabetes, yet the molecular mechanisms linkingGLP-1signaling todiabeticnephropathyremain poorly defined. This study aimed to identify shared molecular targets betweenGLP-1activity anddiabetickidney disease by integrating protein targets ofGLP-1from UniProt with disease-associated genes from ...
GLP-1receptoragonists, regardless of structural homology, reduced the risk of individual MACE components, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes.
GLP-1receptoragonists(GLP-1RAs) exemplify MTMC agents, with pleiotropic anti-inflammatory effects that span pathways such as NF-κB and Toll-like receptors. Their synergy with other agents—such as metformin, which itself synergizes with the phytochemical curcumin (from turmeric)—illustrates the therapeutic potential of MTMC combinations ...
